Double‐blind, vehicle‐controlled clinical investigation of peptide OS‐01 for skin rejuvenation

Alessandra Zonari,Lear E. Brace,Nathaniel H. O. Harder,Claire Harker,Carolina R. Oliveira,Mariana Boroni,Juliana L. Carvalho
DOI: https://doi.org/10.1111/jocd.16242
2024-02-25
Journal of Cosmetic Dermatology
Abstract:Introduction Senescent cells contribute to age‐related tissue deterioration, including the skin, which plays important roles in overall health and social interactions. This study aimed to assess the effects of the senotherapeutic peptide, OS‐01 (a.k.a. Pep 14), on skin. Methods A 12‐week split‐face, double‐blinded, vehicle‐controlled study involving 22 participants was conducted. The OS‐01‐containing formulation was applied to one side of the face, while the other side received an identical control formulation lacking the peptide. Skin characteristics were assessed using instrumental measurements, expert clinical grading, and subjective questionnaires. Results Results showed that the OS‐01 formulation significantly improved one aspect of skin barrier function, as evidenced by reduced trans‐epidermal water loss compared to both baseline and vehicle control. Expert grading and Antera 3D image analysis revealed a reduction in wrinkle appearance and indentation in the periorbital area, and improved skin texture and radiance on both sides of the face, with the OS‐01‐containing formulation demonstrating superior results. Participants also perceived improvements in skin hydration, smoothness, radiance, and overall appearance. Conclusion The findings suggest that the OS‐01 formulation promotes skin health by strengthening the skin barrier, protecting against dehydration, reducing the appearance of wrinkles, and improving skin texture and radiance. These effects are likely attributed to the senotherapeutic properties of OS‐01 in reducing cellular senescence and its associated detrimental effects.
dermatology
What problem does this paper attempt to address?